Last updated: February 28, 2026
What Drug Does NDC 49884-0307 Refer To?
NDC 49884-0307 corresponds to Leqembi (lecanemab), a monoclonal antibody approved by the FDA for early-stage Alzheimer’s disease. It is marketed by Eisai Co. Ltd. in partnership with Biogen.
Market Size and Demographics
Alzheimer’s Disease Market Context
- Global Alzheimer’s market value: estimated at USD 9.2 billion in 2022.
- US prevalence: approximately 6.5 million Americans have Alzheimer’s, projected to reach 7.2 million by 2025.
- Early-stage treatment potential: roughly 1.3 million patients are eligible for disease-modifying therapies like Leqembi annually in the US[1].
Competitive Landscape
- Key competitors include Aduhelm (aducanumab), approved in 2021, and LSN (Lecanemab), which is essentially the same molecule under different branding.
- Currently, no other drugs target amyloid-beta clearance with FDA approval for early disease stages.
Market Penetration and Adoption Trends
- Leqembi's FDA approval in January 2023 catalyzed fast adoption.
- Payers initially restricted coverage; however, recent policy updates have expanded access in Medicare and commercial plans.
- Market penetration remains moderate, with estimates that around 10-15% of eligible patients are receiving the drug as of late 2023.
Pricing Structure and Revenue Estimates
Current Pricing
- List price: approximately USD 26,500 per year per patient (per manufacturer estimates)[2].
- Net price may vary due to rebates, discounts, and patient assistance programs.
Revenue Projections
| Year |
Estimated Patients Treated |
Market Share |
Gross Revenue (USD billions) |
| 2023 |
50,000 |
2.3% |
1.33 |
| 2024 |
150,000 |
7% |
3.98 |
| 2025 |
300,000 |
14% |
7.95 |
Assumptions:
- Steady growth in patient treatment due to increasing diagnosis rates and expanded coverage.
- Market share expansion toward 15% of eligible patients by 2025.
- No significant price reduction or biosimilar introduction within the forecast period.
Price Competition and Biosimilar Development
- Biosimilars for monoclonal antibodies targeting amyloid are in early development stages.
- Patent protections extend until 2030, providing a temporary monopoly.
- Price reductions of 10-20% are possible if biosimilars enter the market, affecting revenue streams post-2030.
Regulatory and Reimbursement Risks
- Off-label use restrictions and payer coverage limitations can suppress market growth.
- Reimbursement policies vary in international markets, affecting global sales potential.
Key Price Forecast Considerations
- Price remains stable at approximately USD 26,500 annually for the next 18-24 months.
- Market expansion could increase total revenues but may pressure per-unit pricing in the medium term.
- Potential price erosion due to biosimilar competition anticipated after patent expiry.
Summary
Leqembi holds a dominant position in the early Alzheimer's treatment market. Its annual treatment cost is USD 26,500, with significant growth potential driven by expanding diagnosis and coverage. Revenue growth is expected to reach nearly USD 8 billion by 2025, assuming steady adoption rates and no major pricing disruptions.
Key Takeaways
- The current USD 26,500/year price offers a high-margin revenue but faces future pressure from biosimilars.
- Market growth depends on diagnostic expansion, payer reimbursement policies, and clinical acceptance.
- Biosimilar entry remains the primary long-term risk, likely impacting prices after patent expiration around 2030.
- US market volume could reach 300,000 treated patients by 2025, translating into USD 8 billion in annual revenue.
FAQs
1. What factors could influence Leqembi’s pricing stability?
Pricing could be affected by biosimilar competition, reimbursement negotiations, and potential discounts for wider access.
2. How does Leqembi compare with other Alzheimer’s therapies?
It is among the first disease-modifying therapies targeting amyloid-beta. Its annual list price surpasses symptomatic treatments but offers potential for long-term disease modification.
3. What is the likelihood of biosimilar entry before 2030?
Biosimilar development is progressing, but regulatory and patent protections delay immediate generic entry, keeping prices stable through the late 2020s.
4. How does regional pricing differ outside the US?
Pricing varies globally, often lower due to healthcare system negotiations and regulatory decisions, influencing overall revenue.
5. What are the key obstacles to market expansion?
Limited diagnosis rates, restrictive payer policies, and clinical hesitancy hamper broader adoption.
References
[1] Alzheimer's Association. (2022). 2022 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 18(4), 700-789.
[2] Eisai Co. Ltd. (2023). Leqembi pricing and reimbursement updates. Retrieved from company website.
